Puma biotech and Specialised Therapeutics signs agreement to commercialize NERLYNX®
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | News Hub Asia
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib) | PharmaShots
puma biotechnology earnings Off 66% - canerofset.com
Puma Study Probes Nerlynx Side Effects | Los Angeles Business Journal
puma biotechnology earnings Off 66% - canerofset.com
Puma Biotech Stock Struggles To Find Its Footing In Crowded Oncology Space (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Still Bullish At These Prices (NASDAQ:PBYI) | Seeking Alpha
These highlights do not include all the information needed to use NERLYNX safely and effectively. See full prescribing information for NERLYNX. NERLYNX ® (neratinib) tablets, for oral use Initial U.S. Approval: 2017
Puma Biotechnology says its breast cancer therapy included in two key NCCN updates
Puma Stock Jumps as Biotech Gets Good News From the FDA | Barron's
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada - Pharmaceutical Business review
Puma Biotechnology and Pierre Fabre's Amendment of NERLYNX License Agreement – Global Legal Chronicle
Access and support | NERLYNX® (neratinib) tablets
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology
Buy Nerlynx (neratinib) Online • Price & Costs | TheSocialMedwork
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
Puma Biotechnology's NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer | Business Wire
Nerlynx Labeling Updated to Include Data on Antidiarrheal Prophylaxis - MPR
Puma Biotechnology: Nerlynx Peak Sales Estimates Have Come Down, But The Intense Selling Still Makes This A Buy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report
Is Puma Biotechnology a Buy? | The Motley Fool
PBYI Stock Nosedives | Puma Biotechnology's Nerlynx Revenue Falls
